It began softly, with boxes of supplies, batteries, and fresh electrode pads arriving at patients’ homes. They were anticipated by some. Many didn’t. In any case, the billing clock was ticking, and those shipments mounted up over time.
Once thought to be a trustworthy pioneer in pain management technology, Zynex Medical is now at the heart of one of the most egregiously intricate medical fraud cases in recent history. Thomas Sandgaard and Anna Lucsok, two of its former top executives, have been charged with federal offenses that range from identity theft to health care fraud. Prosecutors claim that over $873 million was obtained through deceptive billing techniques, which is an astounding amount.
| Category | Details |
|---|---|
| Company Name | Zynex, Inc. (Zynex Medical) |
| Industry | Medical Devices – Pain Management |
| Key Executives Charged | Thomas Sandgaard (Former CEO), Anna Lucsok (Former COO) |
| Charges Filed | Health care fraud, wire fraud, securities fraud, identity theft |
| Amount Allegedly Involved | $873 million+ in fraudulent collections |
| Notable Lawsuits | Allstate ($3M), Travelers ($1M settled), Investor Class Action |
| Federal Action | Grand Jury Indictment, January 2026 |
| Regulator Scrutiny | TriCare payment suspension, SEC disclosures, State-level audits |
| Current CEO | Steven Dyson (appointed August 2025) |
| Core Allegation | Oversupplying patients and inflating insurance bills |
The transition from clinical innovation to courtroom defense is especially startling for a corporation that established its reputation on noninvasive pain management gadgets.
Zynex was able to provide patients with monthly shipments of equipment—often more than what was required or even requested—by utilizing automated fulfillment and subscription models. Bills were sent to insurers. The patients were perplexed. Additionally, both groups occasionally suffered as a result.
The possibility that this supply model, which was formerly thought to be quite effective, was altered has drawn attention in recent months. According to class action lawsuits, investors were misinformed about the company’s ability to sustain its income, and patients were bombarded with gadgets they never requested. Critics contend that this revenue was fabricated, based on overshipment and recurring billing.
In a resolute move, TriCare, the healthcare organization that serves American service members and their families, suspended payments while examining claims. Their substantial yearly income contribution to Zynex meant that the financial consequences were rapid. Zynex revealed a sharp drop in sales in a matter of weeks, going from $46.5 million in the first quarter of 2024 to just $26.6 million in the same quarter of 2025.
According to a first-hand report I read, a former employee compared the shipments to clockwork. They replied, “It just gets billed and billed,” which is one of those subtly depressing quotes that endures.
Citing $3 million in bogus claims, Allstate has filed its own lawsuit as the case progresses. The travelers paid $1 million to resolve theirs. In the meanwhile, shareholder lawsuits contend that the company’s worth was exaggerated, which caused the stock to plummet by 51% after disclosures in March 2025. The disappointment is profound for those who invested in the company’s growth story.
Zynex isn’t shutting down, though. Indeed, it has moved forward, and in August 2025, it announced Steven Dyson as its new CEO. The hiring of Dyson indicates that the business is attempting to change course, or at the very least break with the methods of its previous management. From ambitious growth to careful adjustment, the tone has changed.
The charges go beyond billing. In a disturbing turn of events, prosecutors say Sandgaard paid people to intimidate reporters who started to expose dubious activities as early as 2022. If confirmed, that goes beyond corporate wrongdoing to something much more unsettling.
Businesses that are under investigation frequently have trouble being transparent. But taking revenge on people who look into it? That takes a very different turn.
However, this is not a story that cannot be fixed.
Zynex now has a chance to restore confidence through smart leadership changes and continued collaboration with federal regulators. The investors are observing. Patients are as well, especially those who have actually benefited from the company’s electrotherapy equipment and wish to trust the efficacy of the treatment.
Even though its previous commercial model had serious flaws, Zynex could eventually show that its fundamental technology is still viable by working with insurers and explicitly defining product necessity.
Former workers have started coming forward in the lawsuits, which now cover several jurisdictions. Many of them have detailed internal concerns that were ignored or silenced. Some claim that after raising concerns about the billing volumes, they were fired. Others departed after recognizing that patient need alone was insufficient to explain the patterns.
The Zynex story serves as a warning to medtech startups in their early stages, highlighting how simple it is for process-driven automation to go unchecked. Without strict control, what starts off as scalable supply chain optimization can turn into systemic overreach.
In its best form, Zynex developed a non-opioid solution for treating chronic pain, which is especially helpful for military families and people who don’t want to become dependent. It is still a mission. It has simply been overshadowed by years of unbridled ambition and a narrow-minded emphasis on statistics rather than people.
The core of Zynex’s previous promises can still be preserved when seen through the prisms of accountability and change.
The larger medtech industry has a chance to learn as court cases develop. more transparent charging procedures. independent examination. more robust safeguards for whistleblowers. Every action could result in increased trust as well as compliance.
Zynex is still being investigated at this time, and there is still a long legal path ahead. Nevertheless, businesses like Zynex might redefine what it means to make a course correction—even after the headlines fade—with intentional reform, constant transparency, and a strong dedication to patient-first principles.